Skip to main content
Skip to main content
CURE logo

Direxion Daily Healthcare Bull 3X ETF (CURE)

$119.03 $-3.85 (-3.14%) |CouncilHOLD · 47 · C
Bottom line: HOLD — our Council read (47/100) and AI Score (47/100) broadly agree.
MCap: $151.05M| Vol: 136.9K|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Direxion Daily Healthcare Bull 3X ETF (CURE) trades at $119.03 with AI Score 47/100 (Grade C). Direxion Daily Healthcare Bull 3X ETF (CURE) aims to provide 300% of the daily performance of the Health Care Select Sector Index. Market cap: $151.05M, Sector: Financial services.

Price live · AI analysis from Mar 18, 2026
Direxion Daily Healthcare Bull 3X ETF (CURE) aims to provide 300% of the daily performance of the Health Care Select Sector Index. It operates within the financial services sector, focusing on asset management for healthcare investments.

Analyst Coverage for CURE: CURE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CURE against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.

Council Score · Weighted Average of 3 Disciplines
HOLD 47/100 · C

CURE: the 1 perspectives are evenly split.

How is this calculated? →
Council Score · 8 perspectives · See tabs for details →

Direxion Daily Healthcare Bull 3X ETF (CURE) Financial Services Profile

IPO Year2011

Direxion Daily Healthcare Bull 3X ETF (CURE) is a leveraged exchange-traded fund designed to amplify the daily returns of the Health Care Select Sector Index, catering to investors seeking high-risk, high-reward exposure in the healthcare sector.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Mar 18, 2026

What Is the Investment Thesis for CURE?

The investment thesis for Direxion Daily Healthcare Bull 3X ETF (CURE) hinges on its ability to provide leveraged exposure to the healthcare sector, which has shown resilience and growth potential. With a market cap of $151.05M and a beta of 1.58, CURE is positioned to attract investors looking for high-risk, high-reward opportunities. The healthcare sector is projected to continue growing, driven by demographic trends such as an aging population and increased healthcare spending. Additionally, the ETF's structure allows for potential outsized returns during bullish market conditions, making it a noteworthy option for traders. However, investors must be aware of the inherent risks associated with leveraged ETFs, including the potential for significant losses in volatile markets. The absence of dividends further emphasizes the fund's focus on capital appreciation rather than income generation. Overall, CURE's performance will be closely linked to the movements of the Health Care Select Sector Index, making it essential for investors to monitor sector trends and market conditions.

Based on FMP financials and quantitative analysis

CURE Key Highlights

  • Market capitalization of $151.05M indicates a small-cap profile, appealing to niche investors.
  • Beta of 1.58 suggests higher volatility compared to the broader market, attracting risk-tolerant investors.
  • Seeks to achieve 300% of the daily performance of the Health Care Select Sector Index, offering leveraged exposure.
  • No dividend yield, focusing entirely on capital appreciation.
  • Part of a growing trend of leveraged ETFs that cater to active traders.

Who Are CURE's Competitors?

CURE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
APRW AllianzIM U.S. Equity Buffer20 Apr ETF $37.17 +0.13% $198.67M 50
BJUN Innovator U.S. Equity Buffer ETF $48.87 +0.68% $185.01M 47
CNRG State Street SPDR S&P Kensho Clean Power ETF $107.19 +2.14% $197.97M 47
OALC OneAscent Large Cap Core ETF $40.73 +0.99% $241.03M 49
OCTW AllianzIM U.S. Equity Buffer20 Oct ETF $41.06 +0.32% $188.18M 47
NXDT NexPoint Diversified Real Estate Trust $5.53 +3.08% $285.77M 73
GENB Generate Biomedicines, Inc. $17.03 -2.18% $2.18B 72
SII Sprott Inc. $118.11 +2.72% $3.05B 71

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CURE's Key Strengths?

  • Strong potential for high returns due to leveraged exposure.
  • Established brand recognition in the leveraged ETF market.
  • Focus on a resilient and growing sector, healthcare.
  • No dividend payouts, allowing for reinvestment of returns.

What Are CURE's Weaknesses?

  • High volatility may deter conservative investors.
  • Not suitable for long-term investment strategies.
  • Absence of dividends limits appeal to income-focused investors.
  • Performance can deviate significantly from the index over time.

What Could Drive CURE Stock Higher?

  • Continued growth in the healthcare sector driven by demographic trends.
  • Increased investor interest in leveraged ETFs as trading strategies evolve.
  • Advancements in healthcare technology leading to sector expansion.
  • Potential regulatory changes favoring healthcare investments.
  • Market volatility providing opportunities for short-term traders.

What Are the Key Risks for CURE?

  • High volatility may lead to significant losses for investors.
  • Regulatory risks that could impact the healthcare sector.
  • Competition from other leveraged ETFs could affect performance.
  • Economic downturns may reduce overall healthcare spending.
  • Deviations from the index performance due to compounding effects.

What Are the Growth Opportunities for CURE?

  • Growth opportunity 1: The healthcare sector is expected to grow at a CAGR of 7.9% from 2021 to 2028, driven by advancements in biotechnology and pharmaceuticals. CURE's leveraged exposure positions it to benefit from this growth, potentially amplifying returns for investors who capitalize on sector momentum.
  • Growth opportunity 2: Increasing healthcare spending, projected to reach $8.3 trillion globally by 2025, provides a robust backdrop for CURE. As healthcare expenditures rise, the underlying index's performance may improve, directly benefiting CURE's leveraged strategy.
  • Growth opportunity 3: The ongoing digital transformation in healthcare, including telemedicine and health tech innovations, is reshaping the industry. CURE can leverage this trend as companies within the index adapt and grow, potentially leading to higher returns for the ETF.
  • Growth opportunity 4: Aging populations in developed markets are expected to drive demand for healthcare services and products. With a focus on sectors like pharmaceuticals and medical devices, CURE stands to gain from this demographic shift, enhancing its performance relative to traditional investments.
  • Growth opportunity 5: Regulatory changes favoring healthcare innovation and investment can create favorable conditions for CURE. As governments support healthcare advancements, the underlying index may experience growth, resulting in amplified returns for investors in the ETF.

What Opportunities Does CURE Have?

  • Growing healthcare sector provides a favorable backdrop for performance.
  • Increased investor interest in leveraged ETFs can drive inflows.
  • Technological advancements in healthcare can enhance sector growth.
  • Regulatory support for healthcare innovation can benefit the fund.

What Threats Does CURE Face?

  • Market volatility can lead to significant losses in leveraged ETFs.
  • Regulatory changes may impact the healthcare sector negatively.
  • Competition from other leveraged ETFs may dilute market share.
  • Economic downturns can adversely affect healthcare spending.

What Are CURE's Competitive Advantages?

  • CURE's leveraged structure allows for potentially higher returns compared to traditional ETFs.
  • The fund's focus on the healthcare sector capitalizes on a growing and resilient industry.
  • Direxion's established reputation in the leveraged ETF space provides credibility and trust.
  • The ETF's unique investment strategy attracts a specific segment of risk-tolerant investors.
  • CURE's absence of dividends aligns with the needs of active traders focused on capital gains.

What Does CURE Do?

The Direxion Daily Healthcare Bull 3X ETF (CURE) was launched to provide investors with a vehicle to gain leveraged exposure to the healthcare sector. This exchange-traded fund (ETF) seeks to deliver daily investment results that correspond to 300% of the performance of the Health Care Select Sector Index, before fees and expenses. The fund is designed for short-term trading and is not intended for long-term investment due to the compounding effects of leverage, which can lead to significant deviations from the index performance over extended periods. CURE is part of Direxion's suite of leveraged ETFs, which aim to meet the demands of active traders and investors looking to capitalize on short-term market movements. The ETF does not pay dividends, which aligns with its strategy of reinvesting returns to maximize growth potential in a volatile market. As of now, CURE has a market capitalization of approximately $0.16 billion and a beta of 1.58, indicating higher volatility compared to the broader market. The fund's performance is closely tied to the dynamics of the healthcare sector, which includes pharmaceuticals, biotechnology, medical devices, and healthcare providers. Investors are attracted to CURE for its potential to amplify returns in a sector that is often seen as resilient and growth-oriented.

What Products and Services Does CURE Offer?

  • CURE is an exchange-traded fund (ETF) that seeks to provide 300% of the daily performance of the Health Care Select Sector Index.
  • The fund is designed for short-term trading and is not suitable for long-term investment strategies.
  • CURE does not pay dividends, focusing solely on capital appreciation.
  • It offers investors leveraged exposure to the healthcare sector, which includes pharmaceuticals, biotechnology, and healthcare providers.
  • The ETF is actively managed to track the performance of its underlying index closely.
  • CURE is part of a broader suite of leveraged ETFs offered by Direxion.

How Does CURE Make Money?

  • CURE generates revenue through management fees associated with its ETF structure.
  • The fund's performance is linked to the Health Care Select Sector Index, allowing for leveraged returns.
  • CURE does not distribute dividends, opting to reinvest returns for growth.
  • The ETF's strategy is designed to attract active traders looking for short-term gains in the healthcare sector.
  • Management focuses on maintaining the fund's objectives while navigating market volatility.

What Industry Does CURE Operate In?

The asset management industry, particularly in the realm of ETFs, has seen significant growth over the past decade, with increasing investor interest in specialized sectors such as healthcare. The healthcare sector is projected to grow steadily, driven by factors such as technological advancements, an aging population, and rising healthcare expenditures. CURE fits into this landscape as a leveraged ETF that allows investors to capitalize on the potential upside of the healthcare sector while also exposing them to higher risks. The competitive landscape includes various other leveraged ETFs such as APRW, BJUN, CNRG, OALC, and OCTW, each targeting different aspects of the healthcare and broader financial markets.

Who Are CURE's Key Customers?

  • Active traders seeking leveraged exposure to the healthcare sector.
  • Institutional investors looking for short-term investment strategies.
  • Retail investors interested in capital appreciation rather than income generation.
  • Hedge funds and other investment vehicles that utilize leveraged ETFs for tactical asset allocation.
  • Investors who are bullish on the healthcare sector and willing to accept higher risk.
AI Confidence: 71% Updated: Mar 18, 2026

How Direxion Daily Healthcare Bull 3X ETF Is Valued

Relative to its peer group, CURE's quantitative score of 47/100 is roughly in line with the peer average of 48/100.

CURE Financials

Bull Case vs Bear Case

Bull Case

  • Healthcare sector showing resilience; traders betting on continued demand despite economic headwinds.
  • Recent insider activity suggests confidence in the ETF's holdings; insiders might foresee positive developments in the healthcare industry.
  • Community sentiment indicates a belief in the potential for outsized gains through leveraged exposure to healthcare stocks.
  • Market perception views healthcare as a defensive sector, offering relative stability during market downturns.

Bear Case

  • Leveraged ETFs are inherently risky due to daily resets and potential for amplified losses; traders acknowledge the volatility.
  • Community sentiment expresses concerns about the impact of potential regulatory changes on the healthcare industry.
  • Recent market developments show increased scrutiny on pharmaceutical pricing and healthcare costs, creating uncertainty.
  • Bearish community views highlight the potential for underperformance if the healthcare sector experiences a pullback or consolidation.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026

CURE Latest News

CURE Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CURE.

Price Targets

Wall Street price target analysis for CURE.

CURE MoonshotScore

47/100

What does this score mean?

The MoonshotScore rates CURE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Latest Direxion Daily Healthcare Bull 3X ETF Analysis

What Investors Ask About Direxion Daily Healthcare Bull 3X ETF (CURE) — Financial Services

What does Direxion Daily Healthcare Bull 3X ETF do?

The Direxion Daily Healthcare Bull 3X ETF (CURE) is designed to provide investors with 300% of the daily performance of the Health Care Select Sector Index. It is a leveraged exchange-traded fund that allows investors to gain amplified exposure to the healthcare sector, which includes pharmaceuticals, biotechnology, and healthcare services. The fund does not pay dividends, focusing instead on capital appreciation through short-term trading strategies.

What do analysts say about CURE stock?

Analysts generally view CURE as a high-risk investment due to its leveraged nature, which can lead to significant returns or losses based on market movements. The consensus often highlights the importance of monitoring the healthcare sector's performance, as CURE's success is directly tied to the Health Care Select Sector Index. Key valuation metrics include its beta of 1.58, indicating higher volatility, and the absence of dividends, which influences investor sentiment.

What are the main risks for CURE?

CURE faces several risks, primarily its high volatility, which can result in substantial losses, particularly in bearish market conditions. Additionally, regulatory changes affecting the healthcare sector could negatively impact the performance of the underlying index. The competitive landscape is another factor, as other leveraged ETFs may attract investor interest, potentially diluting CURE's market share. Investors must also consider the economic environment, as downturns can lead to reduced healthcare spending, further affecting the fund's performance.

What are the key factors to evaluate for CURE?

Direxion Daily Healthcare Bull 3X ETF (CURE) holds an AI score of 47/100 (low). Not financial advice.

How frequently does CURE data refresh on this page?

CURE prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.

What has driven CURE's recent stock price performance?

Direxion Daily Healthcare Bull 3X ETF (CURE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong potential for high returns due to leveraged exposure. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CURE overvalued or undervalued right now?

Valuing Direxion Daily Healthcare Bull 3X ETF (CURE) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

What research should beginners do before buying CURE?

Before investing in Direxion Daily Healthcare Bull 3X ETF (CURE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • The analysis is based on current market conditions and available data. Future performance may vary significantly.
Data Sources

Popular Stocks